NCT06508931: An ongoing trial by Miltenyi Biomedicine GmbH
This trial is ongoing. It must report results 5 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06508931 |
|---|---|
| Title | A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory (r/r) Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 4, 2025 |
| Completion date | Dec. 31, 2029 |
| Required reporting date | Dec. 31, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |